Genzyme Will Appeal Lemtrada “Complete Response” After FDA Seeks More Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Rater-blinded design for multiple sclerosis claim netted an approval in Europe but a rejection by FDA, which was concerned about bias related to open label studies.